Pharma firm Wockhardt will be selling its animal health division to France-based Vetoquinol for an estimated Rs 170-180 crore.
Wockhardt has entered into an agreement with Vetoquinol, a veterinary pharma laboratory, to divest the animal health division and the deal is expected to close in the second half of 2009, it said in a statement today.
According to banking sources with the knowledge of the deal, the value of the transaction is estimated to be Rs 170-180 crore.
When contacted, a Wockhardt spokesperson declined to comment on the deal value.
"The transaction is subject to the receipt of the necessary administration approvals and should take effect in the second half of 2009," Wockhardt said in the statement.
Shareholders of the company approved the divestment of the animal health division through a postal ballot on June 1.
Wockhardt said the move to divest its non-core business is a step towards its continued growth plan and a firm focus on its core human pharmaceutical business.
"Wockhardt is re-inventing itself by taking fundamentally strong and positive steps by restructuring and rationalising its business to raise fresh capital and gain investor confidence," the statement added.
The animal health division had net sales of Rs 77 crore for the year ended December 31, 2008.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
